United Therapeutics Q3 Earnings & Sales Beat Estimates [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
Revenues totaled $748.9 million, which beat the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin. See the Zacks Earnings Calendar to stay ahead of market-making news. United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. The company markets two versions of Tyvaso — Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. Both versions are approved for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. The DPI version is less time-consuming to administer and more mobile and convenient than the nebulized one. Tyvaso DPI recorded sales of $274.6 million, up 34% year over year, while sales from nebulized Tyvaso were $159.2 million, up 32%. Overall, Tyvaso sales were $433.8 m
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- Maryland Businesses Celebrate Expansions, Promotions and MilestonesPR Web
- United Therapeutics Corporation to Present at the UBS Global Healthcare ConferenceBusiness Wire
- Metro Aviation Orders BETA Technologies' eVTOL for Medical Transport [Yahoo! Finance]Yahoo! Finance
- United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
UTHR
Earnings
- 10/30/24 - Beat
UTHR
Sec Filings
- 11/19/24 - Form 4
- 11/18/24 - Form 144
- 11/12/24 - Form 4
- UTHR's page on the SEC website